KIAA0754 Inhibitors
KIAA0754 inhibitors encompass a range of chemical compounds that act upon the cytoskeletal components, microtubules, and actin filaments, ultimately leading to the inhibition of KIAA0754's functional activity. Agents such as colchicine, nocodazole, vinblastine, and taxol target microtubule dynamics, either preventing their polymerization or overly stabilizing them, which disrupts the delicate balance required for KIAA0754's role in microtubule-dependent processes. On the other hand, compounds like blebbistatin, latrunculin A, and cytochalasin D directly affect actin filaments. Blebbistatin's inhibition of myosin II ATPase activity, latrunculin A's sequestration of actin monomers, and cytochalasin D's binding to the growing ends of actin filaments, all contribute to the diminished cytoskeletal integrity and transport functions that are vital for KIAA0754's activity in cellular architecture and movement. Similarly, CK-636, by inhibiting the Arp2/3 complex, and SMIFH2, by targeting formin-mediated actin assembly, interfere with actin network formation, further reducing KIAA0754's ability to partake in cytoskeletal organization.
The inhibition of Rho-associated protein kinase by Y-27632 and myosin light chain kinase by ML-7 impairs stress fiber formation, cell contractility, and motility, processes in which KIAA0754 is implicated. Y-27632's action leads to reduced actomyosin contractility, and ML-7's inhibition of MLCK decreases the phosphorylation of myosin light chains, both of which undermine KIAA0754's influence on cellular mechanics. Jasplakinolide's unique role in stabilizing actin filaments presents an intriguing case, where the hyperstabilization could perturb the dynamic equilibrium necessary for KIAA0754's normal functioning. Collectively, these KIAA0754 inhibitors operate through diverse mechanisms but converge on the common outcome of hindering KIAA0754's involvement in maintaining cell shape, motility, and intracellular transport, thereby effectively inhibiting its functional activity within cellular pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin, a structural component of microtubules, leading to the inhibition of microtubule polymerization. KIAA0754 is known to associate with microtubules, and by disrupting microtubule dynamics, colchicine indirectly diminishes the cytoskeletal organization and transport functions of KIAA0754. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol stabilizes microtubules and prevents their depolymerization. This hyperstabilization of microtubules can lead to the inhibition of KIAA0754's normal role in microtubule dynamics and cellular transport. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that disrupts microtubule networks. This disruption can indirectly lead to the inhibition of KIAA0754, which is involved in the regulation of microtubule stability. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine binds to tubulin and inhibits microtubule formation. This action results in the inhibition of KIAA0754 function, as it is involved in microtubule-dependent processes. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is a myosin II inhibitor that impairs myosin's ATPase activity, leading to disruption of myosin-driven processes. Since KIAA0754 is implicated in actin cytoskeletal dynamics, blebbistatin indirectly diminishes KIAA0754's role in actomyosin contractility and cellular movement. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin monomers and prevents their polymerization, leading to disassembly of actin filaments. This affects KIAA0754's ability to interact with the actin cytoskeleton, thereby diminishing its role in cytoskeletal organization. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their depolymerization, potentially interfering with KIAA0754's role in actin filament dynamics and cellular architecture. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that reduces actomyosin contractility by inhibiting Rho-associated protein kinase. This action can lead to the attenuation of KIAA0754's involvement in stress fiber formation and cellular mechanics. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 inhibits formin-mediated actin nucleation and elongation. KIAA0754, being associated with actin dynamics, can have its function diminished by SMIFH2 through the disruption of formin-dependent actin filament assembly. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), which in turn reduces phosphorylation of myosin light chains and decreases actin-myosin interactions. The inhibition of MLCK impairs KIAA0754-mediated cytoskeletal processes and cell motility. | ||||||